News
Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate
Avalon GloboCare Corp., a clinical-stage global developer of cell-based technologies and therapeutics, announced a strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine that can be administered by...
News
Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
Roche announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible...
News
Gilead sets Covid-19 drug candidate remdesivir price at $390 per vial
Gilead Sciences has set the price of its investigational Covid-19 drug remdesivir at $390 per vial for the US and governments of other developed countries.
Current treatment patterns reveal that most patients may require a five-day treatment course, which involves...
Clinical Trials
Astrazeneca: Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1
AstraZeneca announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease.
Selumetinib is co-developed and co-commercialised with MSD Inc., Kenilworth, N.J., US (MSD: known...
News
Stevanato Group: planned investments under the 2020-2023 industrial plan – about 400 million euros to finance the company development
Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, continued its growth in 2019, recording a positive trend on key financial indicators.
Indeed, the Group's consolidated revenues reached € 570.3 million, an...
News
Takeda forms $900m research alliance with Carmine Therapeutics
Japanese pharmaceutical giant Takeda Pharmaceutical has entered into a research collaboration agreement with US-based Carmine Therapeutics for the discovery, development and commercialisation of rare disease therapies.
The partners intend to leverage Carmine’s REGENT technology, based on red blood cell extracellular...
News
CSL Behring to Acquire uniQure’s Late-Stage Hemophilia B Gene Therapy
Global biotherapeutics leader CSL Behring announced that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B from uniQure, a leading gene...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















